AstraZeneca has been granted a patent for an inhaler design that includes a trigger mechanism with a latch and blocker to control the release of medicament. The innovative design allows for precise delivery of medication by inhalation. GlobalData’s report on AstraZeneca gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights AstraZeneca Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AstraZeneca, Personalized cancer vaccines was a key innovation area identified from patents. AstraZeneca's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Inhaler with trigger mechanism for medicament delivery

Source: United States Patent and Trademark Office (USPTO). Credit: AstraZeneca Plc

A newly granted patent (Publication Number: US11883582B2) discloses an innovative inhaler design for the delivery of medication through inhalation. The inhaler features a drive mechanism with a canister drive, biasing means, and trigger mechanism. The trigger mechanism includes a latch in a locked position to prevent movement of the canister drive and a blocker that can be rotated to allow the latch to move to an unlocked position, releasing the biasing means to actuate the canister drive. The inhaler also includes a blocker spring for biasing the blocker and a resetting mechanism to reload the biasing means and reset the trigger mechanism.

Furthermore, the inhaler includes additional features such as an alignment guide for positioning the canister, a return mechanism for automatically returning the canister to a ready-to-fire position after use, and a counting mechanism to track the number of actuations. The design also incorporates a button for moving the blocker, an outer housing with a deflectable portion for user interaction, and a chassis for housing the components. These features aim to enhance the functionality and user experience of the inhaler, providing a comprehensive solution for effective medication delivery through inhalation.

To know more about GlobalData’s detailed insights on AstraZeneca, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies